Barclays
PMCB icon

Barclays’s PharmaCyte Biotech PMCB Stock Holding History

Barclays’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$148 Buy
+192
New +$145 ﹤0.01% 5148

Other funds holding PMCB

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Barclays's PMCB Position: Q2 2026 in Review

Barclays opened a new position in PharmaCyte Biotech (PMCB) in Q2 2026: 192 shares worth $148. The stake represents ﹤0.01% of the portfolio and ranks #5148 among its holdings.

28 funds tracked by Wall St. Rank hold PMCB as of Q2 2026.

  • Barclays held 192 shares of PharmaCyte Biotech worth $148 as of Q2 2026.
  • PharmaCyte Biotech was a new Barclays position in Q2 2026.
  • PharmaCyte Biotech made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5148 holding.
  • 28 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.